ReviewAntiviral therapy2007
Recent advances in the search for antiviral agents against human papillomaviruses.
Review in Antiviral therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- The clinical effectiveness and safety of imiquimod versus podophyllotoxin in the topical treatment of condylomata acuminata: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Molecular interaction of human papilloma virus (HPV) with microRANs: insights into the development of cervical cancer and treatment approaches.Infectious agents and cancer · 2025Review
- C-71980262, a novel small molecule against human papilloma virus-16 E6 (HPV-16 E6) with anticancer potency against cervical cancer: A computational guidedIranian journal of basic medical sciences · 2024Article
- Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.Current medicinal chemistry · 2024Review
- Metabolic Profiling, Antiviral Activity and the Microbiome of Some Mauritian Soft Corals.Marine drugs · 2023Article
- The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies.Viruses · 2022Review
- Pine Needle Extract Applicable to Topical Treatment for the Prevention of Human Papillomavirus Infection.Journal of microbiology and biotechnology · 2021Article
- Stochastic modeling of human papillomavirusearly promoter gene regulation.Journal of theoretical biology · 2020Article
- Recent Insights into the Control of Human Papillomavirus (HPV) Genome Stability, Loss, and Degradation.Journal of clinical medicine · 2015Article
- Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.PloS one · 2013Article
- Therapy of human papillomavirus-related disease.Vaccine · 2012Review
- HPV episome levels are potently decreased by pyrrole-imidazole polyamides.Antiviral research · 2011Article
- Small molecule inhibitors of human papillomavirus protein - protein interactions.The open virology journal · 2011Article
- Molecular mechanisms of human papillomavirus-induced carcinogenesis.Public health genomics · 2009Review
- Replication and partitioning of papillomavirus genomes.Advances in virus research · 2008Review
- Unveiling HPV's hidden link: Cardiovascular diseases and the viral intrigue.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Infection by human papillomavirus (HPV) is extremely common and associated with the development of benign warts or malignant lesions of the skin and mucosa. Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers. The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers. Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients. Thus, the need for antiviral agents to treat HPV-associated diseases remains great, but none currently exist. This article reviews the recent progress made towards the development of antiviral agents to treat HPV infections, from target identification and validation to the discovery of lead compounds with therapeutic potential. Emphasis has been placed on novel low-molecular-weight compounds that antagonize HPV proteins or, alternatively, inhibit cellular proteins which have been usurped by papillomaviruses and are mediating their pathogenic effects.
Indexed as
Identifiers
17668552PMC4646640W2411572535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.